1. Like a Johnson & Johnson, but exclusively focused on biological materials for surgical tissue repair.

2. Think of Elutia as a Medtronic, but specifically developing regenerative implants and patches for cardiovascular and orthopedic surgery.

• CanGaroo: An envelope combined with antibiotics designed to reduce the risk of infection following surgical implantation of an electronic device.
• ProxiCor: A cardiovascular product used as an intracardiac patch or pledget for tissue repairs.
• Tyke: A cardiovascular product for neonates and infants to repair pericardial structures.
• VasCure: A patch material used to repair or reconstruct the peripheral vasculature.
• Fiber VBM, ViBone, and OsteGro V: Human tissue-derived bone allografts designed to protect and preserve native bone cells.
• SimpliDerm: A pre-hydrated HADM designed for the repair or replacement of damaged or inadequate integumental tissues.
• Contract Manufacturing Services: Provides manufacturing services for various products to corporate customers.

C. Randal Mills, Ph. D., President & CEO

Dr. C. Randal Mills is a co-founder of Elutia and has served on its board of directors since November 2015. An internationally recognized expert in regenerative medicine, he has led pioneering biotechnology organizations that have generated over $1 billion in shareholder value for investors. As CEO of Osiris Therapeutics (Nasdaq: OSIR), he played a pivotal role in commercializing five cell-therapy products, accounting for $1.5 billion in sales, and guided the company through an IPO that resulted in a 41-fold increase in shareholder value.

Matthew Ferguson, Chief Financial Officer

Matthew Ferguson assumed the role of Chief Financial Officer at Elutia in September 2020. Prior to joining Elutia, he served as Chief Financial Officer for Bossa Nova Robotics, a privately held robotics company, from September 2018 to July 2020. From January 2011 to August 2018, Mr. Ferguson held various management positions, including Chief Financial Officer, Chief Business Officer, and Co-President, at Avinger, Inc., a publicly traded cardiovascular medical device company.

Michelle LeRoux Williams, Ph. D., Chief Scientific Officer

Dr. Michelle LeRoux Williams is one of the founders of Elutia and brings over 20 years of experience in innovative product development. She previously held the position of Chief Scientific Officer at Osiris Therapeutics, where she invented Osteocel®, recognized as the world's first commercially available stem cell product. Dr. Williams also led the team that secured regulatory approval for the world's first stem cell drug (remestemcel-L) and oversaw the development of successful stem cell products like Grafix® and Cartiform®.

Jeff Hamet, Senior Vice President of Finance

Jeff Hamet brings over 25 years of senior-level finance, accounting, and management expertise, primarily within the life sciences, medical services, and high-technology sectors. From 2013 through 2015, he served as President and Chief Financial Officer of NeurExpand Brain Center LLC. Before that, from 2004 through 2012, Mr. Hamet was the Vice President and Corporate Controller of Martek Biosciences Corporation.

Pete Ligotti, Chief Commercial Officer

Pete Ligotti recently joined Elutia, bringing with him a distinguished 30-year career in the industry. His experience includes 20 years at Integra Life Sciences and a period at NuVasive, where he successfully managed a business. Mr. Ligotti is set to lead Elutia's commercialization efforts, particularly for the upcoming launch of NXT-41X.

Key Risks to Elutia (ELUT)

1. Regulatory Approval, Clinical Efficacy, and Reimbursement Challenges: As a regenerative medicine company developing implantable devices and tissue-derived products, Elutia faces significant risks related to obtaining and maintaining regulatory approvals (e.g., FDA). The success of its products, such as CanGaroo, ProxiCor, and various allografts, hinges on demonstrating clinical efficacy and safety through rigorous trials. Furthermore, securing adequate reimbursement from healthcare payers is crucial for market adoption and commercial success. Failure to navigate these regulatory, clinical, and reimbursement landscapes effectively could severely limit product sales and market penetration.
2. Supply Chain and Quality Control for Human Tissue-Derived Products: Elutia offers several human tissue-derived products, including Fiber VBM, ViBone, and OsteGro V bone allografts. The reliable sourcing, processing, and stringent quality control of human tissue are critical and complex aspects of its operations. Risks include potential disruptions in the supply of suitable donor tissue, issues with tissue viability or safety, contamination risks, and strict regulatory oversight concerning human tissue acquisition and processing. Any failure in this supply chain or quality control could lead to product recalls, reputational damage, and an inability to meet market demand.
3. Intense Competition and Rapid Technological Advancement: The regenerative medicine and medical device markets are highly competitive and characterized by rapid technological innovation. Elutia competes with established companies and emerging players developing similar or alternative solutions for cardiovascular, orthopedic/spinal, and soft tissue reconstruction markets. The risk exists that competitors may introduce more effective, safer, or more cost-efficient products, or that new technologies could render Elutia's current offerings less competitive or obsolete, impacting its market share and profitability.

Elutia (symbol: ELUT) operates in several addressable markets with its regenerative medicine products. While specific market sizes for individual products like CanGaroo, ProxiCor, Tyke, and VasCure are not explicitly detailed, the addressable markets for the broader categories of these products have been identified.

Cardiac Implantable Electronic Device (CIED) Infection Prevention (for CanGaroo)

CanGaroo, an envelope with antibiotics designed to reduce infection risk after electronic device implantation, addresses a segment within the larger Cardiac Implantable Electronic Device (CIED) or Cardiac Rhythm Management (CRM) market. The global cardiac rhythm management devices market was valued at approximately USD 16.1 billion in 2024 and is projected to reach USD 24.08 billion by 2032, growing at a CAGR of 5.23% from 2025 to 2032. Other estimates place the global CIED market at USD 32.6 billion in 2025, with projections to reach USD 61.24 billion by 2033 at a CAGR of 8.20%. North America is a dominant region in this market, holding approximately 45% of the global CRM market share.

Cardiovascular Repair (for ProxiCor, Tyke, and VasCure)

Elutia's cardiovascular products, including ProxiCor (intracardiac patch), Tyke (pericardial repair), and VasCure (peripheral vasculature patch), target segments within the vascular and cardiovascular repair patches markets.

• The global vascular patches market was valued at USD 589.55 million in 2024 and is expected to reach USD 1,174.71 million by 2032, growing at a compound annual growth rate (CAGR) of 9.00% during the forecast period. North America leads this market, holding a 45.05% share in 2024.
• A broader "cardiovascular and soft tissue repair patches market" was valued at USD 4.84 billion globally in 2024 and is expected to grow to USD 10 billion by 2033, exhibiting a CAGR of 8.4%. North America dominated this combined market in 2021, accounting for 37.6% of total sales.

Orthopedic/Spinal Repair (for Fiber VBM, ViBone, and OsteGro V)

Elutia's human tissue-derived bone allografts, Fiber VBM, ViBone, and OsteGro V, address the significant bone allografts market.

• The global bone allografts market size was estimated at USD 1.90 billion in 2024 and is projected to grow to USD 3.52 billion by 2030, with a CAGR of 9.4% from 2025 to 2030.
• North America accounted for the largest global revenue share, representing 40.0% of the global bone allografts market in 2024. The U.S. bone grafts and substitutes market (which includes allografts) was valued at USD 1.31 billion in 2024 and is anticipated to reach approximately USD 2.14 billion by 2034.

Soft Tissue Reconstruction (for SimpliDerm)

SimpliDerm, a pre-hydrated Human Acellular Dermal Matrix (HADM) for repairing or replacing damaged integumental tissues, falls within the soft tissue repair market.

• The global soft tissue repair market was valued at USD 14.4 billion in 2024 and is expected to reach USD 24.3 billion by 2034, growing at a CAGR of 5.1% from 2025 to 2034.
• North America dominates the soft tissue repair market, holding a market share of 48.7%. The U.S. soft tissue repair industry alone was valued at USD 5.1 billion in 2024.

Elutia (ELUT) anticipates several key drivers for its future revenue growth over the next 2-3 years, largely stemming from its strategic repositioning and focus on drug-eluting biomatrix technologies:

1. Commercial Launch and Adoption of NXT-41x in Breast Reconstruction: Elutia's primary future growth driver is the anticipated commercialization of its next-generation antibiotic-eluting biomatrix, NXT-41x, designed for the breast reconstruction market. The company projects FDA clearance for the base matrix (NXT-41) in the second half of 2026 and for the antibiotic-eluting NXT-41x by mid-2027, with a commercial launch targeted for the latter half of 2027. This product aims to address a significant unmet need in the estimated $1.5 billion U.S. breast reconstruction market.
2. Growth of Existing SimpliDerm and Cardiovascular Product Lines: Following the divestiture of its BioEnvelope business, Elutia is now centered on its SimpliDerm and cardiovascular patch products. The company reported a 131% surge in cardiovascular revenue in Q4 2025, driven by a transition to a direct distribution model. Continued optimization of sales and distribution for these existing product lines, along with potential growth in Women's Health sales (SimpliDerm), are expected to contribute to revenue.
3. Expansion of the Drug-Eluting Biomatrix Platform: Elutia's strategic transformation emphasizes its core competency in developing drug-eluting biomatrix (DEB) products. The success of its prior drug-eluting biologic platform (EluPro, which was sold to Boston Scientific) validates this technology. Beyond NXT-41x, the company's underlying platform technology creates opportunities for the development and introduction of additional product offerings and market expansions in the future, leveraging its integrated R&D, manufacturing, and commercialization model.

Capital Allocation Decisions (Last 3-5 Years)

Share Issuance

• Elutia, then Aziyo Biologics, went public in 2020, raising net proceeds of $43.0 million at $17 per share.
• In December 2021, the company closed a $14.0 million private placement (PIPE financing) by issuing Class A and Class B common stock at a price of $4.24 per share.
• A capital raise in December 2022 generated net proceeds of $13.8 million from equity.

Inbound Investments

• Aziyo Biologics secured a $14.0 million private placement in December 2021, with Birchview Capital leading the investment, and participation from existing investors including funds affiliated with Deerfield Management Company and HighCape Capital.

Capital Expenditures

• In the most recent 12-month period for which data is available, Elutia (formerly Aziyo Biologics) reported capital expenditures of $659,000.
• The company is directing resources towards the advancement and commercialization of its NXT-41x antibiotic-eluting biomatrix, targeting the breast reconstruction market.
• Proceeds from the $88 million sale of its BioEnvelope business are intended to fully fund the development and launch of the NXT-41x platform.